Cogent Biosciences, Inc. (COGT)
Automate Your Wheel Strategy on COGT
With Tiblio's Option Bot, you can configure your own wheel strategy including COGT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COGT
- Rev/Share 0.0375
- Book/Share 1.3544
- PB 23.9658
- Debt/Equity 0.3913
- CurrentRatio 4.1938
- ROIC -1.3743
- MktCap 4534687838.0
- FreeCF/Share -2.0499
- PFCF -19.3256
- PE -13.0795
- Debt/Assets 0.2207
- DivYield 0
- ROE -1.2025
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | COGT | Stifel | Hold | Buy | -- | $40 | Nov. 10, 2025 |
| Upgrade | COGT | Wedbush | Neutral | Outperform | -- | $38 | Nov. 10, 2025 |
| Initiation | COGT | Stifel | -- | Hold | -- | $16 | Oct. 16, 2025 |
| Initiation | COGT | Raymond James | -- | Strong Buy | -- | $30 | Sept. 3, 2025 |
| Initiation | COGT | Scotiabank | -- | Sector Outperform | -- | $17 | March 7, 2025 |
| Downgrade | COGT | Needham | Buy | Hold | -- | -- | Dec. 11, 2024 |
News
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Positive
Cogent Biosciences, Inc. soared 120% after positive Phase 3 PEAK study results for bezuclastinib in imatinib-resistant GIST patients. COGT's bezuclastinib showed a 50% reduction in disease progression risk and superior objective response rates versus standard of care. Strong PEAK data de-risks upcoming readouts and supports blockbuster revenue projections, with analysts targeting $1.5bn peak sales and a $3-4bn valuation.
Read More
Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Positive
Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib in 2nd-line GIST. Company's combination therapy showed a significant mPFS improvement (16.5 vs. 9.2 months) and higher ORR (46% vs. 26%) over Sunitinib monotherapy in 2nd-line GIST patients. Upcoming catalysts include NDA filings for GIST in 1H 2026 and NonAdvSM by end of 2025, plus phase 2 APEX results for AdvSM in December 2025.
Read More
Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Cogent Biosciences, Inc. ( COGT ) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 10, 2025 8:00 AM EST Company Participants Christi Waarich - Senior Director of Investor Relations Andrew Robbins - President, CEO & Director Conference Call Participants Neeta Somaiah Anupam Rama - JPMorgan Chase & Co, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Amanda Acosta-Ruiz - Leerink Partners LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good …
Read More
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: October 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced updated preclinical data from the company's potent and selective pan KRAS(ON) inhibitor in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, October 22-26, 2025.
Read More
Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Cogent Biosciences, Inc. (NASDAQ:COGT ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Andrew Robbins - President, CEO & Director Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Good morning. Thank you for coming to the 2025 Citi Biopharma Conference in Boston.
Read More
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
Read More
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Published: July 07, 2025 by: Benzinga
Sentiment: Positive
Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder.
Read More
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.
Read More
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo.
Read More
About Cogent Biosciences, Inc. (COGT)
- IPO Date 2018-03-29
- Website https://www.cogentbio.com
- Industry Biotechnology
- CEO Andrew R. Robbins
- Employees 205